Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Verkazia cyclosporine Severe vernal keratoconjunctivitis, pediatric (≥4 years) Reimburse with clinical criteria and/or conditions Complete
Revestive Teduglutide Short bowel syndrome Reimburse with clinical criteria and/or conditions Complete
Revestive teduglutide Short Bowel Syndrome (SBS), pediatrics Reimburse with clinical criteria and/or conditions Complete
TBC exagamglogene autotemcel Sickle cell disease (SCD) Pending
Cubicin Daptomycin Skin and skin structure infections & bacteremia Do not list Complete
Tecentriq atezolizumab Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Tecentriq Atezolizumab Small Cell Lung Cancer (SCLC) Do not reimburse Complete
Champix Varenicline tartrate Smoking-cessation List with clinical criteria and/or conditions Complete
Votrient Pazopanib Hydrochloride Soft Tissue Sarcoma Do not reimburse Complete
N/A Nab-paclitaxel Solid tumours Active